Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

We recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2; those interim results covered a period of 57 days after the first vaccination.

How the Novavax Vaccine Works

The Maryland-based company Novavax has developed a protein-based coronavirus vaccine called NVX-CoV2373. The vaccine produced strikingly high levels of antibodies in early clinical trials.

Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic

Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), the cause of coronavirus disease 2019 (COVID- 19), is a transmissible virus that infects the upper and lower respiratory tract, leading to a high viral titer in saliva and respiratory secretions.

COVID-19 as the Leading Cause of Death in the United States

The current exponential increase in coronavirus dis- ease 2019 (COVID-19) is reaching a calamitous scale in the United States, potentially overwhelming the health care system and causing substantial loss of life.

Feds Authorize $22 Billion to Boost Vaccine Rollout

The CDC will send $3 billion to the states to boost a lagging national COVID-19 vaccination program.